# LifeSci Venture Partners

> LifeSci Venture Partners is a VC fund backing Biotechnology and Health Care. See 43 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 43
- Last investment: May 2026
- Lead investor: 5%
- Fund size: $23M
- Last fund: Feb 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/lifesci-venture-partners/
- X (Twitter): https://twitter.com/lifesciadvisors
- Website: https://www.lifesciventure.com/

LifeSci Venture Partners is an early-stage investment firm that invests in early-stage life sciences and healthcare companies. The firm provides companies in the life sciences industry with comprehensive solutions to communications and investor outreach. Their investment principals have broad-ranging life sciences experience including public andprivate investing, deal structuring, investment banking, equity capital markets, equity research, and bench research both basic science and applied.

## Contacts

5 contacts available for LifeSci Venture Partners. Shizune tracks 5 team members at LifeSci Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lifesci-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 27 | 63% |
| Health Care | 17 | 40% |
| Therapeutics | 13 | 30% |
| Pharmaceutical | 11 | 26% |
| Medical | 9 | 21% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 14 | 33% |
| Series C | 10 | 23% |
| Series A | 9 | 21% |
| Post-IPO Equity | 4 | 9% |
| Venture - Series Unknown | 2 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 31 | 72% |
| China | 1 | 2% |
| Israel | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew A. Sauter | Consulting CFO | 0 | https://shizune.co/investors/profile/andrew-a-sauter |
| Andrew McDonald | Founding Partner&CEO | 0 | https://shizune.co/investors/profile/andrew-mcdonald-bcea |
| Andrew McDonald | Founding Partner&CEO | 0 | https://shizune.co/investors/profile/andrew-mcdonald-6204 |
| Ira Kalfus | CMO | 0 | https://shizune.co/investors/profile/ira-kalfus-d1c9 |
| Scott Janssen | Managing Director | 0 | https://shizune.co/investors/profile/scott-janssen |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M | Post-IPO Equity | May 18, 2026 |  |
| Achieve Life Science | Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M | Post-IPO Equity | Apr 16, 2026 |  |
| Yarrow | Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease. | $200M | Venture - Series Unknown | Dec 17, 2025 |  |
| VeraDermics | Veradermics is a dermatology-focused biopharmaceutical company that develops treatments for common skin and hair conditions. Its lead drug candidate, VDPHL01, is an extended-release oral minoxidil being tested in Phase 3 clinical trials for pattern hair loss in both women and men. The company also has pipeline programs targeting conditions such ascommon warts, molluscum contagiosum, and atopic dermatitis. | $150M | Series C | Oct 16, 2025 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M | Series C | Mar 19, 2025 |  |
| Candid Therapeutics | Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $370M | Series A | Sep 09, 2024 |  |
| Averto Medical | Savage Medical manufactures devices for medical use, enabling patients to get solutions for gastrointestinal diseases. They offer solutions for patients suffering from gastrointestinal diseases. | $30M | Series A | May 07, 2024 |  |
| ProfoundBio | ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. | $112M | Series B | Feb 13, 2024 |  |
| Beta Bionics | Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $100M | Series D | Aug 30, 2023 |  |
| MOMA Therapeutics | MOMA Therapeutics operates as a biotechnology company. MOMA Therapeutics discover the next generation of precision medicines by targeting the molecular machines that underlie human disease. | $150M | Series B | May 10, 2022 |  |

10 of 43 investments shown.

## Co-investors
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 11 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 10 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 9 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 9 deals together
- [Venrock Healthcare Capital Partners](https://shizune.co/investors/profile/venrock-healthcare-partners) — VC Fund, 9 deals together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 8 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does LifeSci Venture Partners invest in?

LifeSci Venture Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 43 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact LifeSci Venture Partners?

Public channels for LifeSci Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LifeSci Venture Partners?

The team at LifeSci Venture Partners includes Andrew A. Sauter (Consulting CFO), Andrew McDonald (Founding Partner&CEO) and Andrew McDonald (Founding Partner&CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co